 |
|
|
| |
Renal Safety Through 96 Weeks in a Phase 2 Trial (P011) of Islatravir and Doravirine in Treatment-Naïve Adults With HIV-1
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Frank A. Post1; Ciaran J. McMullan2; Giovanni Di Perri3; Jean-Michel Molina4; Stephanie O. Klopfer2; Anjana Grandhi2; Karen Eves2; Deborah Hepler2; Carey Hwang2; Todd A. Correll2
King's College Hospital NHS Foundation Trust, London, UK; 2Merck & Co., Inc., Kenilworth, NJ, USA; 3University of Turin, Turin, Italy; 4University of Paris Diderot and St-Louis Hospital, Paris, France
|
| |
|
|
|
|
|
